U.S. Food and Drug Administration Grants Priority Review to KEYTRUDA Combo with Padcev for Muscle-Invasive Bladder Cancer
FDA Prioritizes Review of KEYTRUDA® and KEYTRUDA QLEX™ Combinations with Padcev® for Cisplatin-Eligible Muscle-Invasive Bladder Cancer Patients Merck & Co., known as MSD outside the United States and Canada, has…
Synthetic Design Lab Debuts First Logic-Gated ADC at AACR 2026, Delivering ≥10X Enhanced Targeted Cancer Cell Killing
Synthetic Design Lab reveals first logic-gated ADC at AACR 2026 with ≥10x enhanced targeted cancer cell killing Synthetic Design Lab, an emerging innovator in the field of antibody-drug conjugates (ADCs)…
Lundbeck Showcases Real-World Improvements in Migraine-Related Cognitive Symptoms with VYEPTI® at AAN 2026
Lundbeck highlights AAN 2026 data showing real-world improvements in migraine-related cognitive symptoms with VYEPTI® (eptinezumab-jjmr) Lundbeck has presented new real-world data from its ongoing INFUSE study at the American Academy…
Zai Lab Highlights Preclinical Data Showing ZL-1503 Delivers Rapid Itch Relief and Anti-Inflammatory Effects in Atopic Diseases
Zai Lab shares preclinical data showing ZL-1503 delivers rapid itch relief and reduces inflammation in atopic diseases Zai Lab Limited has announced promising new preclinical findings for ZL-1503, its internally…
Agenus Highlights Phase II Data Showing Durable Survival and Immune Reprogramming in PD-1 Refractory Gastroesophageal Cancer
Agenus highlights durable survival and immune reprogramming in PD-1 refractory gastroesophageal cancer with Botensilimab combo Agenus Inc., a company focused on advancing immuno-oncology innovation, has reported new clinical findings from…
Zai Lab Highlights Zoci’s Strong Brain Tumor Responses in SCLC and Neuroendocrine Cancers
Zai Lab reports strong, rapid brain metastasis responses with Zocilurtatug Pelitecan in SCLC and other neuroendocrine cancers Zai Lab Limited has unveiled compelling new clinical and preclinical data highlighting the…
Akamis Bio Reports Promising Early Phase 1b FORTRESS Results for NG-350A in MMR-Proficient Locally Advanced Rectal Cancer
Akamis Bio Reports Promising Early Findings from Phase 1b FORTRESS Trial of NG-350A in MMR-Proficient Locally Advanced Rectal Cancer Akamis Bio, a biotechnology company focused on transforming the treatment landscape…
Onchilles Pharma Unveils NEU-002 Preclinical Data at AACR 2026
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate Selection Onchilles Pharma, a privately held biotechnology company focused on…
HSS Study Assesses Non-Opioid Pain Management After Orthopedic Surgery
HSS Study Evaluates Non-Opioid Pain Relief Following Orthopedic Surgery A retrospective study presented at the 51st Annual Regional Anesthesiology and Acute Pain Medicine Meeting by investigators at Hospital for Special…
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) to Prevent RSV Lower Respiratory Disease in Infants
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season Merck & Co.—known as MSD…
Drug Farm to Present Encouraging Phase 1b Results for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™
Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™ Drug Farm has announced promising early clinical and immunologic data from its…
Byondis to Showcase Novel ADC Platform Data at the 2026 American Association for Cancer Research Meeting
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026 Byondis B.V., an independent biotechnology company focused on developing next-generation targeted…